https://scholars.lib.ntu.edu.tw/handle/123456789/623990
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Chen S.-C. | en_US |
dc.contributor.author | Huang Y.-H. | en_US |
dc.contributor.author | Chen M.-H. | en_US |
dc.contributor.author | Hung Y.-P. | en_US |
dc.contributor.author | Lee R.-C. | en_US |
dc.contributor.author | YU-YUN SHAO | en_US |
dc.contributor.author | Chao Y. | en_US |
dc.date.accessioned | 2022-10-25T03:30:38Z | - |
dc.date.available | 2022-10-25T03:30:38Z | - |
dc.date.issued | 2022 | - |
dc.identifier.issn | 1471-2407 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85122956162&doi=10.1186%2fs12885-022-09173-4&partnerID=40&md5=8b8ec554a2d33d1f72e4cad989a81437 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/623990 | - |
dc.publisher | BioMed Central Ltd | - |
dc.relation.ispartof | BMC Cancer | - |
dc.title | Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1186/s12885-022-09173-4 | - |
dc.identifier.pmid | 35016637 | - |
dc.identifier.scopus | 2-s2.0-85122956162 | - |
dc.relation.journalvolume | 22 | - |
dc.relation.journalissue | 1 | - |
item.fulltext | no fulltext | - |
item.openairetype | journal article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.orcid | 0000-0001-7334-1912 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。